Amifampridine Tablets (Ruzurgi) and Liver disease
Result of checking the interaction of drug Amifampridine Tablets (Ruzurgi) and disease Liver disease for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Amifampridine is extensively metabolized by N-acetyltransferase 2 (NAT2) and hepatic impairment may cause an increase in exposure. The effects of amifampridine have not been studied in patients with hepatic impairment. It is recommended to start treatment with amifampridine in patients with any degree of hepatic impairment at the lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions. Consider dosage modification or discontinuation in patients with hepatic impairment as clinically appropriate.
Generic Name: amifampridine
Brand Name: Firdapse, Ruzurgi
Synonyms: Amifampridine
Amifampridine Tablets (Ruzurgi) - choroba wątroby 
Amifampridine Tablets (Ruzurgi) - doença hepática 
Amifampridine Tablets (Ruzurgi) - penyakit hati 
Amifampridine Tablets (Ruzurgi) - penyakit hati 
Amifampridine Tablets (Ruzurgi) - malattia del fegato 
Amifampridine Tablets (Ruzurgi) - maladie du foie 
Amifampridine Tablets (Ruzurgi) - Leber erkrankung 
Amifampridine Tablets (Ruzurgi) - enfermedad del higado 
Amifampridine Tablets (Ruzurgi) - заболевание печени 
Amifampridine Tablets (Ruzurgi) - karaciğer hastalığı 
Amifampridine Tablets (Ruzurgi) - مرض الكبد 
Amifampridine Tablets (Ruzurgi) - 肝病